These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 9308763

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Arginine506 to glutamin mutation in the factor V gene in infancy and childhood: evidence of fibrinolytic impairment.
    Nowak-Göttl U, Vielhaber H, Grohmann J, Schneppenheim R, Koch HG.
    Eur J Pediatr; 1997 Mar; 156(3):195-8. PubMed ID: 9083758
    [Abstract] [Full Text] [Related]

  • 3. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene.
    Nowak-Göttl U, Sträter R, Dübbers A, Oleszuk-Raschke K, Vielhaber H.
    Blood Coagul Fibrinolysis; 1996 Oct; 7(7):684-8. PubMed ID: 8958390
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
    Zöller B, Svensson PJ, He X, Dahlbäck B.
    J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
    [Abstract] [Full Text] [Related]

  • 6. Fibrinolytic response to venous occlusion compared to physical stress test in young patients with coronary artery disease.
    Nikfardjam M, Graf S, Beckmann R, Hornykewycz S, Koller-Strametz J, Binder BR, Huber K.
    Thromb Haemost; 1999 Sep; 82 Suppl 1():80-4. PubMed ID: 10695493
    [Abstract] [Full Text] [Related]

  • 7. Coagulation factor V (Arg506-->Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting.
    Moor E, Silveira A, van't Hooft F, Tornvall P, Blombäck M, Wiman B, Rydén L, Hamsten A.
    Thromb Haemost; 1998 Aug; 80(2):220-4. PubMed ID: 9716141
    [Abstract] [Full Text] [Related]

  • 8. APC resistance in childhood thromboembolism: diagnosis and clinical aspects.
    Nowak-Göttl U, Schneppenheim R, Vielhaber H.
    Semin Thromb Hemost; 1997 Aug; 23(3):253-8. PubMed ID: 9255906
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage.
    Glueck CJ, Pranikoff J, Aregawi D, Haque M, Zhu B, Tracy T, Wang P.
    Metabolism; 2005 Oct; 54(10):1345-9. PubMed ID: 16154434
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
    Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Auteri A, Bruni F.
    Int J Clin Pharmacol Res; 2001 Oct; 21(3-4):147-55. PubMed ID: 12067144
    [Abstract] [Full Text] [Related]

  • 15. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K, Szaflarska-Popławska A, Dymek G, Kotschy M.
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [Abstract] [Full Text] [Related]

  • 16. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
    Lang NN, Gudmundsdóttir IJ, Boon NA, Ludlam CA, Fox KA, Newby DE.
    J Am Coll Cardiol; 2008 Jul 01; 52(1):33-9. PubMed ID: 18582632
    [Abstract] [Full Text] [Related]

  • 17. Genetic markers of fibrinolytic responses of older persons to exercise training.
    Kulaputana O, Ghiu I, Phares DA, Ferrell RE, Macko RF, Goldberg AP, Hagberg JM.
    Int J Sports Med; 2006 Aug 01; 27(8):617-22. PubMed ID: 16874588
    [Abstract] [Full Text] [Related]

  • 18. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V, Marino R, Scaraggi FA, Di Bari L, Giannoccaro F, Petronelli M, Ranieri P, Tannoia N, Schiraldi O.
    Blood Coagul Fibrinolysis; 1999 Oct 01; 10(7):409-16. PubMed ID: 10695766
    [Abstract] [Full Text] [Related]

  • 19. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C.
    Clin Endocrinol (Oxf); 2006 Mar 01; 64(3):323-9. PubMed ID: 16487444
    [Abstract] [Full Text] [Related]

  • 20. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
    Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M.
    J Clin Invest; 1998 Feb 01; 101(3):667-76. PubMed ID: 9449701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.